JPMorgan Chase & Co. Downgrades Dyne Therapeutics (NASDAQ:DYN) to Underweight

Key Points

• JPMorgan downgraded Dyne Therapeutics to Underweight from Neutral and set a $10 price target, implying roughly 51% downside from the stock’s $20.31 opening price.
• Analyst sentiment remains mixed: despite the downgrade and other bearish ratings, Dyne has a consensus rating of Moderate Buy with an average target price of $33.33. The company also missed quarterly earnings estimates, reporting a loss of $1.08 per share versus the expected $0.75 loss.
• Insiders sold approximately 4.15 million shares worth nearly $99.7 million over the past three months, while the stock remains heavily institutionally owned at 96.68%; some sales were attributed to tax-withholding obligations and a prearranged trading plan.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was downgraded by research analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating in a research note issued to investors on Wednesday, Marketbeat reports. They currently have a $10.00 target price on the stock. JPMorgan Chase & Co.'s target price points to a potential downside of 50.76% from the stock's current price.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Monday, August 17th. Sanford C. Bernstein raised their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research note on Wednesday, May 13th. Finally, Robert W. Baird set a $26.00 target price on Dyne Therapeutics in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $33.33.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $20.31 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of -6.10 and a beta of 1.08. The stock's fifty day moving average price is $24.82 and its two-hundred day moving average price is $20.49. Dyne Therapeutics has a one year low of $11.92 and a one year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). On average, equities analysts forecast that Dyne Therapeutics will post -3.47 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 2,160,516 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the sale, the director directly owned 428,946 shares in the company, valued at approximately $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. The trade was a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 4,150,974 shares of company stock valued at $99,697,629. 9.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Creative Planning increased its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company's stock valued at $196,000 after buying an additional 986 shares during the period. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics during the first quarter worth about $26,000. Caxton Associates LLP lifted its stake in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company's stock worth $158,000 after acquiring an additional 1,627 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after acquiring an additional 2,465 shares during the period. Finally, Strs Ohio bought a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $51,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month results from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The presentations will include updated safety data and comparisons with a matched natural-history cohort, potentially providing evidence of sustained treatment benefit. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, with topline results still expected in the first quarter of 2027. DYNE-101 also holds FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, which could support an expedited regulatory process if the data are favorable. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity was unusually high, with 20,532 calls purchased versus average volume of roughly 464. The surge may indicate speculative positioning ahead of clinical updates, but it does not establish that the company’s fundamentals have improved.
• Negative Sentiment: Investor sentiment weakened after a competing DM1 therapy failed in a Phase 3 study. Although the result does not directly assess DYNE-101, it raised concerns about the DM1 treatment landscape and increased scrutiny of Dyne’s forthcoming data. RTT News report on rival DM1 failure
• Negative Sentiment: CEO John Cox and other insiders reported sales of shares, including transactions around $18.88 and $24.35. The filings state that the sales were used to cover tax withholding obligations on vested equity awards, and each insider retained a substantial position; nevertheless, the cluster of sales may add to cautious sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.